Kodiak Sciences treats first patient in Phase 1 study of KSI-501

Kodiak Sciences announced that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak’s Antibody Biopolymer Conjugate Platform to enter the clinic. The Phase 1 study of KSI-501 is being conducted in the USA as an open-label, multiple ascending dose study and initially is enrolling patients with diabetic macular edema. The primary objectives of the Phase 1 study are to evaluate ocular and systemic safety and to establish a maximum tolerated dose.